{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:43:34Z","timestamp":1784979814013,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Itch is the most burdensome symptom in atopic dermatitis (AD) and prurigo nodularis (PN) and is associated with significant psychological distress, sleep deprivation and impaired quality of life. Achieving rapid control of itch is expected to minimize symptomatology and disease burden. Nemolizumab, which targets the interleukin 31 (IL\u201031) pathway, rapidly relieved itch in Phase 2 trials; thus, a post hoc analysis of four pivotal randomized controlled clinical trials of nemolizumab in AD and PN was performed to further evaluate the improvement of itch over the first 14\u2009days of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from ARCADIA 1 and 2 in AD (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091728) and OLYMPIA 1 and 2 in PN (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009560) were analysed. Patients reported itch intensity and sleep disturbance daily. Differences in the proportion of itch and sleep responders (patients with \u22654\u2010point improvement from baseline in peak pruritus numerical rating scale [PP\u2010NRS] or sleep disturbance [SD\u2010NRS] score) between nemolizumab and placebo groups were calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nemolizumab rapidly reduced itch in AD (ARCADIA 1 and 2), with a difference versus placebo in PP\u2010NRS responders apparent by Day 2 (pooled data: 10.7% vs. 2.9%; 95% CI: 5.6\u201310.1;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) that steadily increased through Day 14. Nemolizumab also reduced itch rapidly in PN (OLYMPIA 1 and 2); a difference versus placebo occurred by Day 2 (pooled data: 17.2% vs. 3.7%; 95% CI: 6.8\u201316.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Early improvement (Day 2) was also observed in sleep in nemolizumab\u2010treated patients. In pooled analyses in AD, 9.9% (nemolizumab) versus 4.6% (placebo; 95% CI: 2.8\u20137.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001) were SD\u2010NRS responders and in PN, 13.4% versus 4.3% (95% CI: 4.0\u201313.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0013). Itch and sleep response data in individual studies were consistent with the pooled data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis confirms previously reported data that nemolizumab relieves itch and sleep disturbance by Day 2 in patients with moderate\u2010to\u2010severe AD and PN, indicating that targeting the IL\u201031 pathway presents an important way to achieve rapid itch response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70250","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:30:10Z","timestamp":1765906210000},"page":"867-875","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"first","affiliation":[{"name":"Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus University Hospital M\u00fcnster  M\u00fcnster Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina B.","family":"Elmariah","sequence":"additional","affiliation":[{"name":"University of California San Francisco Center for Itch and Neurosensory Disorders  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"Dr Philip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, Miami Itch Center University of Miami  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Pink","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology Guy's and St Thomas' NHS Foundation Trust and King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yeon","family":"Cheong","sequence":"additional","affiliation":[{"name":"Galderma Laboratories, LP  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Galderma Laboratories, LP  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarif K.","family":"Jabbar\u2010Lopez","sequence":"additional","affiliation":[{"name":"Galderma Research and Development  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Ulianov","sequence":"additional","affiliation":[{"name":"Galderma Research and Development  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-2478","authenticated-orcid":false,"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[{"name":"Galderma Laboratories, LP  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology The George Washington School of Medicine and Health Sciences  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae052"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2025.03.009"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01203-0"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00149-X"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.08.009"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16309"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3778"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3726"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20148"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00999-9"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17870"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14791"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.638325"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2022.03.005"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.048"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301333"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17218"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4796"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18377"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00962-8"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20783"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.446"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5538"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01303"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00738-4"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.060"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02320-9"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.01.028"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70250","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70250","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70250","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:22:35Z","timestamp":1777533755000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jdv.70250"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70250","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"2025-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}